01943nas a2200301   4500000000100000008004100001260001700042653004300059653001200102653003000114653001600144653001100160653002300171653001200194653003800206653002300244653001800267653001300285653001600298100001500314700001600329700001600345245010700361300001100468490000600479520114200485022001401627       1985                            d  c1985 Oct-Dec10aChemical and Drug Induced Liver Injury10aDapsone10aDrug Therapy, Combination10aEthionamide10aHumans10aLeprostatic Agents10aleprosy10aPatient Acceptance of Health Care10aPatient Compliance10aProthionamide10aRifampin10aWest Indies1 aCartel J L1 aGallais J J1 aGrosset J H00a[Acceptability, compliance and tolerance of daily polychemotherapy by leprosy patients in Guadeloupe].  a339-550 v33 a<p>From January 1980 to December 1984, 418 leprosy patients were treated in Guadeloupe with a daily multiple drug regimen using rifampin as an essential drug. The analysis of the data collected during this period of times gives the possibility of estimating the patient's approval, tolerance and attendance to this treatment. The approval is satisfactory in new cases of leprosy and in ancient cases relapsed under dapsone monotherapy but less in inactive ancient patients already treated with dapsone monotherapy. Attendance of the 418 patients to the multiple drug regimen is satisfactory too and similar to the attendance of patients treated with dapsone monotherapy in Guadeloupe and to the attendance of patients with monthly multiple drug regimen in another Caribbean country. Reactions did not occur with higher gravity or frequency than in patients under dapsone monotherapy. The high incidence of hepatitis (14%) due to the toxicity of protionamide in the combination rifampin-protionamide-dapsone make obligatory the monthly assessment of the liver functions in multibacillary patients treated with such a drug combination.</p>  a0001-5938